Significant Revenue Growth
Seer reported a 32% year-over-year revenue growth, reaching $4.1 million in the second quarter of 2025.
Strong Balance Sheet
The company ended the quarter with approximately $263 million in cash, cash equivalents, and investments.
Launch of Proteograph ONE Workflow
Seer launched the high-throughput Proteograph ONE assay and SP200 automation instrument, doubling throughput and reducing runtime by 30%.
Landmark Population Scale Study
Announced a 20,000 sample study with Korea University, representing the largest deep plasma proteomics study of its kind.
Successful Share Repurchase Program
Repurchased approximately 13% of net total shares outstanding, utilizing $20 million of the $25 million share repurchase program.
Partnership with Thermo Fisher
Expanded partnership to co-market the Proteograph Product Suite, enhancing commercial reach and enabling population-scale deep proteomics.